The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Chronic myeloid leukemia (CML) is the best example of successful targeted therapy. Today,
the overall survival of patients with CML treated by using tyrosine kinase inhibitors (TKIs) is …

The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread
perception that chronic myeloid leukemia (CML) has become another chronic disease …

BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine
kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a …

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic
myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We …

Abstract Treatment discontinuation is considered one of the main goals of therapy for
patients with chronic myeloid leukemia. Several criteria are felt to be necessary to consider …

BACKGROUND Several studies have demonstrated that approximately one‐half of patients
with chronic myeloid leukemia (CML) who receive treatment with tyrosine kinase inhibitors …

Background: Tyrosine kinase inhibitors (TKI) have dramatically improved survival in chronic
myeloid leukemia (CML) with a high proportion of patients reaching deep molecular …

The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …